Trexquant Investment LP bought a new position in G1 Therapeutics Inc (NASDAQ:GTHX) in the 3rd quarter, HoldingsChannel reports. The fund bought 13,308 shares of the company’s stock, valued at approximately $696,000.
A number of other institutional investors have also recently added to or reduced their stakes in GTHX. Bank of New York Mellon Corp increased its holdings in G1 Therapeutics by 1,497.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,262,991 shares of the company’s stock worth $54,890,000 after acquiring an additional 1,183,940 shares in the last quarter. Voya Investment Management LLC increased its holdings in G1 Therapeutics by 7,889.9% in the 2nd quarter. Voya Investment Management LLC now owns 449,834 shares of the company’s stock worth $19,550,000 after acquiring an additional 444,204 shares in the last quarter. BlackRock Inc. increased its holdings in G1 Therapeutics by 32.0% in the 2nd quarter. BlackRock Inc. now owns 1,690,360 shares of the company’s stock worth $73,462,000 after acquiring an additional 409,300 shares in the last quarter. BB Biotech AG purchased a new stake in G1 Therapeutics in the 2nd quarter worth approximately $15,324,000. Finally, FMR LLC increased its holdings in G1 Therapeutics by 6.4% in the 3rd quarter. FMR LLC now owns 5,216,663 shares of the company’s stock worth $272,780,000 after acquiring an additional 313,931 shares in the last quarter. 71.02% of the stock is owned by institutional investors.
Shares of GTHX opened at $38.23 on Monday. G1 Therapeutics Inc has a 1 year low of $18.03 and a 1 year high of $69.57. The company has a market cap of $1.42 billion, a price-to-earnings ratio of -10.71 and a beta of 1.09.
In other G1 Therapeutics news, VP Jennifer K. Moses sold 750 shares of the stock in a transaction that occurred on Wednesday, September 5th. The shares were sold at an average price of $59.60, for a total transaction of $44,700.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Rajesh Malik sold 3,776 shares of the stock in a transaction that occurred on Thursday, November 15th. The shares were sold at an average price of $39.75, for a total transaction of $150,096.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 60,359 shares of company stock valued at $2,958,267. Insiders own 15.92% of the company’s stock.
Several equities research analysts recently issued reports on GTHX shares. Zacks Investment Research raised shares of G1 Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 8th. Cowen reissued a “buy” rating on shares of G1 Therapeutics in a report on Thursday, August 9th. JPMorgan Chase & Co. increased their target price on shares of G1 Therapeutics from $58.00 to $63.00 and gave the stock an “overweight” rating in a report on Friday, August 10th. BTIG Research started coverage on shares of G1 Therapeutics in a report on Monday, September 10th. They issued a “buy” rating and a $80.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $79.00 target price on shares of G1 Therapeutics in a report on Monday, September 17th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $74.00.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/12/03/trexquant-investment-lp-buys-shares-of-13308-g1-therapeutics-inc-gthx.html.
About G1 Therapeutics
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Read More: What is an Initial Public Offering (IPO)?
Want to see what other hedge funds are holding GTHX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for G1 Therapeutics Inc (NASDAQ:GTHX).
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.